| Literature DB >> 28412809 |
Natthakan Thongon1, Nittaya Boonmuen1, Kanoknetr Suksen1, Patsorn Wichit1, Arthit Chairoungdua1, Patoomratana Tuchinda2, Apichart Suksamrarn3, Wipawee Winuthayanon4, Pawinee Piyachaturawat1.
Abstract
Diarylheptanoids from Curcuma comosa, of the Zingiberaceae family, exhibit diverse estrogenic activities. In this study we investigated the estrogenic activity of a major hydroxyl diarylheptanoid, 7-(3,4 -dihydroxyphenyl)-5-hydroxy-1-phenyl-(1E)-1-heptene (compound 092) isolated from C. comosa. The compound elicited different transcriptional activities of estrogen agonist at low concentrations (0.1-1 μM) and antagonist at high concentrations (10-50 μM) using luciferase reporter gene assay in HEK-293T cells. In human breast cancer (MCF-7) cells, compound 092 showed an anti-estrogenic activity by down-regulating ERα-signaling and suppressing estrogen-responsive genes, whereas it attenuated the uterotrophic effect of estrogen in immature ovariectomized rats. Of note, compound 092 promoted mouse pre-osteoblastic (MC3T3-E1) cell differentiation and the related bone markers, indicating its positive osteogenic effect. Our findings highlight a new, nonsteroidal, estrogen agonist/antagonist of catechol diarylheptanoid from C. comosa, which is scientific evidence supporting its potential as a dietary supplement to prevent bone loss with low risk of breast and uterine cancers in postmenopausal women.Entities:
Keywords: Curcuma comosa; bone; breast cancer; diarylheptanoid; estrogen agonist; estrogen antagonist; phytoestrogens; uterus
Mesh:
Substances:
Year: 2017 PMID: 28412809 DOI: 10.1021/acs.jafc.7b00769
Source DB: PubMed Journal: J Agric Food Chem ISSN: 0021-8561 Impact factor: 5.279